Our Pipeline

Our team aspires to deliver finite and curative protease inhibitors treatments for the world’s most prevalent and devastating diseases.

Current development

Program Indication In-silico In-vitro Preclinical Clinical Patent
NIL-FH01 Undisclosed In prep
NIL-FH02 Undisclosed
NIL-FH03 Undisclosed